改良皮下注射硼替佐米在多发性骨髓瘤治疗中的临床价值研究

目的 分析改良皮下注射硼替佐米在多发性骨髓瘤治疗中的临床价值.方法 72例多发性骨髓瘤患者,采用随机抽样法分为参照组和实验组,每组36例.两组患者均使用硼替佐米进行治疗,参照组患者采用传统常规注射,研究组患者采用改良皮下注射.比较两组患者药物注射后躯体疼痛程度和注射药物后不良事件发生情况.结果 药物注射后,研究组患者视...

Study on the clinical value of modified subcutaneous injection of bortezomib in the treatment of multiple myeloma

Objective To analyze the clinical value of modified subcutaneous injection of bortezomib in the treatment of multiple myeloma.Methods A total of 72 patients with multiple myeloma were divided into reference group and experimental group according to random sampling method,with 36 cases in each group.The research group was treated with conventional injection of bortezomib,and the research group was treated with modified subcutaneous injection of bortezomib.The degree of physical pain after drug injection and the occurrence of adverse events after drug injection were compared between the two groups.Results After drug injection,the visual analogue scale(VAS)score of the research group was(3.05±2.21)points,which was lower than(5.21±2.19)points of the reference group,and the difference was statistically significant(P<0.05).After drug injection,the reference group had 3 cases of erythema,5 cases of drug extravasation,4 cases of induration,and 3 cases of local swelling,with incidence of adverse events as 41.67%(15/36);the research group had 2 cases of local swelling and 1 case of induration,with incidence of adverse event rate as 8.33%(3/36).The incidence of adverse events of the research group was lower than that of the reference group,and the difference was statistically significant(P<0.05).Conclusion Modified subcutaneous injection has low pain degree and high safety in the treatment of multiple myeloma,which has clinical value.